VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Boston Research & Management Inc.

Boston Research & Management Inc. lowered its position in shares of VanEck Biotech ETF (NASDAQ:BBH) by 2.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,351 shares of the company’s stock after selling 370 shares during the quarter. Boston Research & Management Inc. owned 0.48% of VanEck Biotech ETF worth $2,080,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Tidemark LLC acquired a new position in VanEck Biotech ETF during the fourth quarter worth $34,000. Mather Group LLC. acquired a new position in shares of VanEck Biotech ETF during the 2nd quarter worth $46,000. Red Lighthouse Investment Management LLC acquired a new stake in shares of VanEck Biotech ETF in the second quarter valued at about $51,000. Commonwealth Equity Services LLC boosted its holdings in VanEck Biotech ETF by 1.1% during the first quarter. Commonwealth Equity Services LLC now owns 30,426 shares of the company’s stock worth $5,061,000 after buying an additional 340 shares in the last quarter. Finally, Principal Securities Inc. acquired a new position in VanEck Biotech ETF during the fourth quarter worth about $66,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

BBH opened at $180.78 on Friday. The stock’s 50 day simple moving average is $178.81 and its 200 day simple moving average is $169.58. VanEck Biotech ETF has a 1-year low of $142.51 and a 1-year high of $183.64.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.